financetom
Business
financetom
/
Business
/
Cement producer Titan America seeks up to $3.3 billion valuation in US IPO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cement producer Titan America seeks up to $3.3 billion valuation in US IPO
Jan 28, 2025 5:48 AM

(Reuters) - Titan America is seeking a valuation of up to $3.32 billion in its New York initial public offering, the Belgium-based cement producer said on Tuesday.

The IPO comes as European companies increasingly look to list their U.S. units in New York in search of deeper capital markets, higher valuations, and a wider investor base.

Titan Cement International last year announced its intention to carve-out its U.S. business and list the unit in New York in early 2025 to raise funds for growth.

The unit is offering 9 million shares, while parent Titan Cement is selling 15 million shares priced between $15 and $18 each to raise up to $432 million.

Citigroup and Goldman Sachs are the lead underwriters for the offering.

Titan America will list on the New York Stock Exchange under the symbol "TTAM."

(Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Shinjini Ganguli)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
E3 Lithium and Axens Sign Bilateral MOU for Sale of Lithium Carbonate and Supply of Lithium Selective Sorbent
E3 Lithium and Axens Sign Bilateral MOU for Sale of Lithium Carbonate and Supply of Lithium Selective Sorbent
Oct 16, 2025
08:01 AM EDT, 10/16/2025 (MT Newswires) -- E3 Lithium ( EEMMF ) , which lost 3.6% Wednesday, and Axens, a global provider of clean energy solutions and technologies, signed a non-binding memorandum of understanding that contemplates both the sale of lithium carbonate by E3 Lithium ( EEMMF ) to Axens and for Axens to supply E3 Lithium ( EEMMF )...
Praxis Precision Medicines Says Phase 3 Trials of Ulixacaltamide in Essential Tremor Meet Goals
Praxis Precision Medicines Says Phase 3 Trials of Ulixacaltamide in Essential Tremor Meet Goals
Oct 16, 2025
08:02 AM EDT, 10/16/2025 (MT Newswires) -- Praxis Precision Medicines ( PRAX ) said Thursday that two phase 3 pivotal studies of its investigational drug ulixacaltamide in essential tremor met key primary and secondary endpoints, with the patients showing clinically meaningful improvements in tremor control and daily function. One study, which enrolled 473 patients, met its primary endpoint of an...
BRIEF-GCL Executes MoU To Acquire Madeviral, Aiming To Accelerate Global Growth In Game Marketing And Publishing Support
BRIEF-GCL Executes MoU To Acquire Madeviral, Aiming To Accelerate Global Growth In Game Marketing And Publishing Support
Oct 16, 2025
Oct 16 (Reuters) - GCL Global Holdings Ltd ( GCL ): * GCL EXECUTES MOU TO ACQUIRE MADEVIRAL, AIMING TO ACCELERATE GLOBAL GROWTH IN GAME MARKETING AND PUBLISHING SUPPORT * GCL GLOBAL HOLDINGS LTD ( GCL ) - TO EXPLORE ACQUIRING UP TO 51% OF MADEVIRAL Source text: Further company coverage: ...
Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor
Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor
Oct 16, 2025
08:03 AM EDT, 10/16/2025 (MT Newswires) -- Rakovina Therapeutics ( RKVTF ) Thursday said new preclinical data from its ATR inhibitor program will be presented in a poster session at next week's conference on molecular targets and cancer therapeutics in Boston, Massachusetts. DNA damage repair (DDR) enzymes, including ataxia telangiectasia and Rad3-related protein (ATR), are crucial for maintaining stability in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved